Postpartum haemorrhage (PPH) continues to be the leading cause of maternal mortality in middle and low-income countries including India. Much advancement has been made in the field of treatment of PPH, but not much progress has been made in the field of prevention, where one of its main component is administration of uterotonic, preferably oxytocin, immediately after birth of the baby. In many low- and middle income countries, the efficacy of oxytocin cannot be assured since access to sustained cold-chain is unavailable. Regarding other uterotonics: Ergometrine degrades when exposed to heat or light and Misoprostol degrades rapidly when exposed to moisture. Innovation in the manufacture of carbetocin has met the stability requirements in hot and humid climates. Both Carbetocin and Oxytocin are approved drugs for active managemrent of third stage of labour (AMTSL) and prevention of PPH. This study has been undertaken to evaluate the uterotonic effect of carbetocin compared to oxytocin for the prevention of primary PPH in emergency or elective Caesarean delivery. The purpose of this study is to determine if carbetocin is superior to oxytocin in terms of reduction in the need of additional uterotonic agents and the occurrence of PPH.